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Background: Patients with chronic obstructive pulmonary disease (COPD) often experience depression and anxiety,
but little information is available regarding Chinese patients with these conditions. The present study assessed
depression and anxiety in Chinese patients with COPD.
Methods: A case–controlled study was designed with 1100 patients with COPD enrolled in the case group
and1100 residents without COPD and respiratory symptoms selected as the control group. Anxiety and depression
in both groups were evaluated using the Hospital Anxiety and Depression Scale (HADS). The body mass index,
degree of airflow obstruction, dyspnea, and exercise capacity (BODE ) index was used to assess COPD severity.
Binary logistic regression models were used to test the association between anxiety and depression.
Results: The patients with COPD were more likely than controls to experience depression (cases, HADS 10.5 ± 3.6,
prevalence 35.7%; controls, HADS 8.7 ± 2.7, prevalence 7.2%) and anxiety (cases, HADS 10.4 ± 3.1, prevalence 18.3%;
controls, HADS 8.6 ± 2.1, prevalence 5.3%). Subjects with anxious and depressive symptoms had poorer health
outcomes including a higher BODE index, a shorter 6-minute-walk distance (6MWD), more dyspnea, and a higher St
George’s respiratory questionnaire (SGRQ) score. The prevalence of anxious and depressive symptoms increased
with increasing BODE scores. On the basis of binary logistic regression, the BODE index was significantly correlated
with anxiety (OR = 1.47, p < 0.001) and depression (OR = 1.51, p < 0.001). Anxious and depressive symptoms were
also associated with several factors including younger age, female sex, higher education level, lower household
income and history of smoking.
Conclusions: This study confirmed the high prevalence of anxiety and depression in Chinese outpatients with
COPD. Patients with COPD who had anxiety and/or depression had a poorer health-related quality of life.
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Chronic obstructive pulmonary disease (COPD) is a
leading cause of disability and death worldwide, with
population prevalence rates of 5–13% [1-3]. Prevalence
rates are directly related to tobacco smoking and indoor
air pollution, and are expected to rise as smoking rates
continue to increase, notably among women and in
developing countries [1,3]. By 2030, COPD is expected
to represent the third leading cause of death in middle-
income countries [4]. COPD is characterized by poorly
reversible limitations of airflow and dyspnea [5], but it is
not limited to the lung. Some patients develop system-
atic manifestations, including exercise limitations [6,7],
peripheral muscle dysfunction [6,8], and malnutrition
[9]. Two of the most common and least-treated co-
morbidities of COPD are anxiety and depression [10].
Increasing evidence suggests that anxiety and depression
may have direct impacts on health status, hospitalization
and exacerbation of COPD [11,12], rather than being
consequences or markers of disease severity. Thus,
detecting depression or anxiety in patients with COPD
is of great importance. Although the close correlation
between anxiety and depression is well known, few stud-
ies have examined their simultaneous occurrence in
patients with COPD. Moreover, there are few studies
assessing and comparing anxiety and depression levels
among patients with COPD in China.
The aim of the present cross-sectional study was to in-
vestigate the levels and frequency of anxiety and depres-
sion among community-based patients with COPD. In
addition, we evaluated the correlation between anxiety,




This is a cross-sectional survey conducted between
March and May 2008 in the rural areas of Xuzhou area.
A cluster randomized sampling strategy was used.
According to Chinese alphabetical sorting, one out of
every nineteen communities was selected as a study com-
munity. Twelve communities were selected out of 238
communities. All patients in the primary care stations of
the 12 selected communities were included. Based on age
(±1 year), sex, education level, average number of family
members and marital status, healthy participants who
lived in the same villages as the patients with COPD were
selected as control subjects. All sampled subjects were
invited to participate in the study during home visits.
Study population
Patients met the following criteria: (1) COPD diagnosed
by the standards of the Global Initiative for Chronic
Obstructive Lung Disease (GOLD); (2) no fever, noworsening of respiratory symptoms, no X-ray or medica-
tion changes within four weeks before recruitment; (3)
no primary diagnosis of asthma; and (4) no previous lung
volume reduction surgery, lung transplantation, or pneu-
monectomy. According to the sampling criteria, 1100
healthy participants were selected as control subjects.
Demographic data
General characters such as age, sex, education level, aver-
age number of family members, marital status, smoking
status (current-, ex- or never-smoker) and household net
income were recorded based on patient reports. Subject
weight and height were measured before carrying out
pulmonary function tests and the body mass index (BMI)
was calculated by dividing the weight in kilograms by
height in meters squared. Education level was categor-
ized as below high school, high school, or beyond high
school education. Cigarette smoking was defined as hav-
ing smoked at least 100 cigarettes in one’s lifetime.
Assessment of anxiety and depression
Anxiety and depression were measured using the Hos-
pital Anxiety and Depression Scale (HADS) [13,14]. The
HADS has been specifically developed for detection of
anxiety and depression in patients with somatic condi-
tions. It is a validated screening tool for symptom sever-
ity in cases of anxiety and depression in patients with
chronic diseases (including COPD) [11,12,14]. It is
divided into an anxiety subscale (HADS-A) and a de-
pression subscale (HADS-D) both containing seven
items, rated 0–3, giving a possible maximum score for
anxiety and depression of 21. Scores <8 indicate no clin-
ical distress; scores from 8 to 10 indicate possible psy-
chiatric morbidity; and scores ≥11 indicate probable
pathologic levels of distress [13]. The Mandarin-Chinese
HADS was also translated and validated in our popula-
tion (unpublished data).
Assessment of pulmonary function
Spirometry and bronchodilator response tests were car-
ried out by trained professionals according to the stan-
dardized guidelines of the American Thoracic Society
(ATS) [15]. Patients carried out the pulmonary function
test at least 12 hours after the withdrawal of inhaled
bronchodilators. Patients performed spirometry at 15
and 60 minutes after inhaling salbutamol (200 μg).
GOLD stages were defined as described in the updated
GOLD (2006 edition) [16].
Assessment of quality of life
Health-related quality of 1ife (HRQL) was measured
with Saint George’s Respiratory Questionnaire (SGRQ).
The questionnaire is a widely used questionnaire specific
to respiratory disease. It consists of 50 items and is
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respiratory symptoms), activities (effects due to im-
pairment of mobility or physical activity), and effects
(psychosocial effects of the disease) [17]. Scores were
weighted using empirically derived weights. The scores
range from 0 to l00 for the three subscales with a sum-
mary total score. Higher scores indicate worse health
status; 0 indicates no impairment and 100 indicates
maximal impairment [18].
Assessment of dyspnea
Dyspnea was measured using the Medical Research
Council (MRC) dyspnea scale. The MRC dyspnea scale
classifies breathlessness into six grades (0 to 5) according
to self-perceived breathlessness during daily activities [19].
Assessment of exercise capacity
The six-minute walking distance test (6MWD) was car-
ried out according to ATS guidelines. Each patient was
ordered to walk as rapidly as possible in a solid and flat
corridor for six minutes. The test was repeated twice
with an interval of at least 30 minutes [20]. The better
walking distances for each patient were recorded.
Assessment of anxiety and depression impact on the
health outcomes of patients with COPD
We used the validated BODE index, which is a multi-
modal measure of disease severity, to assess COPD se-
verity for each subject who was affected by anxiety and
depression [21]. The BODE index is based on the BMI,
the degree of airflow obstruction measured by forced ex-
piratory volume in one second (FEV1), grade of dyspnea
assessed by the modified MRC dyspnea scale [22], and
exercise capacity measured by the 6MWD test. Each
component is assigned a specific index and the total
score ranges from 0 to 10 points (higher scores indicate
greater severity). The BODE index predicts death and
other poor outcomes with COPD [21,23,24]. The BODE
index can be divided into four quartiles:quartile I is a
score of 0–2; quartile II is a score of 3–4; quartile III is a
score of 5–6; and quartile IV is a score of 7–10 [21,25].
Statistical analysis
The computer-based analysis program Statistical Pack-
age for Social Science (SPSS) version 13.0 was used for
all calculations. The minimal statistical significance level
for all analyses was p <0.05. Group comparisons for cat-
egorical variables were performed using Pearson’s chi-
square test or Fisher’s exact test. To compare groups of
patients, we used ANOVAs for normally distributed data
and the Kruskal–Wallis test for non-normally distribu-
ted data. For comparisons between two groups, Student’s
t-test and the Mann–Whitney U test were used for nor-
mally and non-normally distributed data, respectively.Pearson’s correlation was used to assess the association
between anxiety and depression. To evaluate the risk
factors for depression, multivariate logistic regression
analysis was performed, incorporating all factors that
obtained values of p <0.05 in the bivariate analyses.
Ethical approval for the study was given by the Ethics
Committee of the Xuzhou Center for Disease Control
and Prevention, and the Regional Ethical Vetting Board,
Xuzhou, China. Informed consent was obtained from all
participants.
Results
General characteristics of participants
There were 1683 patients with COPD receiving care in
the 12 selected communities. According to the patient
screening criteria, 1145 patients (68.0%) met the screen-
ing criteria and 538 patients (32.0%) did not meet the
screening criteria. Out of 1145 matching participants,
1100 matching participants had completed the question-
naires, while 45 paired subjects (12 patients, 33 controls)
did not complete the questionnaires. There was no sig-
nificant difference in age between responders and non-
responders [mean age 62.0 (SD 11.6) and 61.8(SD 12.0)
years, respectively; p =0.76].
The demographic characteristics of the 1100 healthy
controls and the 1100 patients with COPD who com-
pleted the study are summarized in Table 1. The median
age of all 2200 subjects was 62 years (range, 39 y to 76
y) and most (75.2%) were males. These values were simi-
lar for both the control and COPD groups. Disease se-
verity according to the GOLD stage is shown in Table 2.
The presence of dyspnea had the following distribution:
160 patients (14.5%), MRC 0; 465 (42.3%), MRC l; 355
(32.3%), MRC 2; 91(8.3%) MRC 3; and 29 (2.6%), MRC
4, with a median of 1 (P5-P95, 0–3). These patients
showed a mean FEVl of 1.27 L (SD, 0.36 L), a mean
6MWD of 445 m (SD, 91 m), a mean BMI of 23.3 k/m2
(SD, 2.8 k/m2), a mean SGRQ total score of 43.4 (SD,
17.6), and a median BODE index of 2 (P5-P95, l–6).
Females manifested a significantly higher frequency of
depressive symptoms (44.3% vs. 34.0%, p <0.001) and
lower frequency of anxious symptoms (16.2% vs. 19.3%,
p <0.001) than males (Table 3).
Prevalence of anxious symptoms in patients with COPD
Table 1 shows the mean scores on the HADS-A for
patients with COPD. The mean anxiety scores of
patients with COPD were higher than those of healthy
controls (p <0.05). Not only did the patients with COPD
show a higher median anxiety score, but the patients
with COPD were also significantly more likely than
healthy controls to report anxious symptoms (patients:
18.3% vs. controls: 5.3%, p <0.01). Compared to the
patients with COPD who had no anxious symptoms, the
Table 1 Baseline characteristics of the study population
according to disease status






Female sex 273 (24.8) 273 (24.8) ≥0.05
Educated level to high school
or beyond
21 (1.9) 21 (1.9) ≥0.05
Smoking history
Past smoker 264 (24.0) 12 (1.1) <0.05
Current smoker 226 (20.5) 235 (21.4)
Never smoker 610 (55.5) 853 (77.5)
HADS-A ≥ 8 201 (18.3) 58 (5.3) <0.05
HADS-D ≥ 8 393 (35.7) 79 (7.2) <0.05
Mean (SD) or median (quartile)
Age 63.2 (40–75) 62.1 (39–76) ≥0.05
Average number of family
members
2.86 (1–4) 2.86 (1–4) ≥0.05
Annual net income per
family (yuan)
17002 (440) 17477 (469) <0.05
BMI (kg/m2) 23.3 (2.8) 23.4 (3.0) ≥0.05
FEV1(L) 1.27 (0.36) 2.55 (0.68) <0.05
FEV1, % of predicted value 45.2 (10.8) 88.6 (9.2) <0.05
FEV1/FVC 47.9 (11.5) 83.6 (9.3) <0.05
6MWD (m) 445.0 (91.0) 580.1 (99.8) <0.05
HADS-A score 4.8 (2.3) 3.1 (1.6) <0.05
HADS-D score 5.4 (2.6) 3.5 (2.4) <0.05
HADS: Hospital Anxiety and Depression Scale: HADS-A: HADS—anxiety; HADS-
D: HADS—depression; FEV1, forced expiratory volume in one second; FVC,
forced vital capacity; BMI:body mass index; 6MWD: six-minute walking
distance; MRC: Medical Research Council; SGRQ: Saint George’s Respiratory
Questionnaire: BODE: body mass index, degree of airway obstruction, dyspnea
and exercise capacity; Possible anxiety (8 ≤ HADS-A ≤ l0) and probable anxiety
(HADS-A ≥ 11) were combined and referred to as anxiety (HADS-A ≥ 8).
Possible depression (8 ≤ HADS-D ≤ l0) and probable depression (HADS-D ≥ 11)
were combined and referred to and as depression (HADS-D ≥ 8).
Table 2 Depressive and anxious symptoms of the study popu
Variables Healthy
controls I (n = 163) II (n = 46
HADS-A
Total score 3.1 (0–12) 6.1(2–15) 6.3(4–1
HADS-A ≥ 8 58 (5.3) 14(8.6) 70(15.2
HADS-D
Total score 3.3 (0–13) 5.8(3–15) 6.5(5–1
HADS-D ≥ 8 79(7.2) 25(15.3) 118(25.
BODE index NA 2.4(1–6) 2.7(1–7
HADS-A, HADS—anxiety; HADS-D,HADS—depression.
Values are expressed as the median (range) or number (%).
a p < 0.01 compared to healthy controls.
b p < 0.01 compared to mild-to-severe COPD.
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smaller means of BMI and 6MWD and had higher med-
ians of MRC, BODE index, and SGRQ score (Table 3).
In a subgroup analysis of patients with COPD, increased
frequency of anxious symptoms was correlated with
increased disease severity according to the GOLD stages
(χ2 = 27.47, p <0.001) (Table 2). The prevalence of anx-
ious symptoms also increased with increasing BODE
quartiles (χ2 = 78.69, p <0.0001) (Table 2).
Prevalence of depressive symptoms in patients with
COPD
From Table 1, we knew that the HADS–D scores and
frequency of depressive symptoms for the healthy con-
trols and the patients with COPD differed significantly.
The patients with COPD had higher HADS–D scores
and greater frequency of depressive symptoms in com-
parison to the healthy controls (p <0.05). In comparison
to the patients with COPD who had no depressive symp-
toms, the patients with COPD who had depressive
symptoms had smaller means of BMI, FEV1, and
6MWD, and had higher medians of MRC, BODE index,
and SGRQ score (Table 3). In a subgroup analysis of
patients with COPD, increased frequency of depressive
symptoms was correlated with increased disease severity
according to the GOLD stages (χ2 = 133.03, p <0.001)
(Table 2). The prevalence of depressive symptoms in
patients with COPD increased as BODE index increased
(χ2 = 102.34, p <0.0001) (Table 2).
Relationship between anxiety and depression in COPD
patients
According to the HADS scores, 165 (42.0%) depressive
patients with COPD presented with concomitant anxious
symptoms, and 145(72.1%) of the anxious patients pre-
sented with depressive symptoms (Table 3). Compared tolation
COPD
0) III (n = 289) IV (n = 188) total
7) 6.5(5–18) 7.0(6–19)b 6.7 (2–19)a
) 65(22.5) 52(27.7)b 201(18.3)a
7) 6.8(5–18) 7.3(7–20)b 6.7(3–20)a
7) 123(42.6) 127(67.6)b 393(35.7)a
) 3.3(1–8) 4.1(2–8)b 2.9(1–8)
Table 3 Disease-related characteristics of the COPD patients according to anxiety or depression status
Anxiety status p Value Depression status p Value
Yes (n = 201) No (n = 899) Yes (n = 393) No (n = 707)
HADS-A score (mean, sd) 10.4(3.1) 3.5(2.1) <0.05 NA NA NA
HADS-D score (mean, sd) NA NA NA 10.5(3.6) 4.1(3.3) <0.05
BMI (kg/m2) (mean, sd) 22.5(2.7) 23.7(2.8) <0.05 23.4(2.9) 22.2(3.0) <0.05
FEV1 (L) 1.29(0.35) 1.30(0.33) >0.05 1.25(0.34) 1.29(0.35) <0.05
6MWD (m) (mean, sd) 408.5(78.6) 456.8 (95.5) <0.05 401.5(88.5) 460.6(100.5) <0.05
MRC score (mean, 5th-95th) 2(0–4) 1(0–2) <0.05 2(0–4) 1(0–2) <0.05
BODE index (mean, 5th-95th) 4(1–8) 2.5(1–6) <0.05 3.5(1–8) 2.5(1–6) <0.05
SGRQ score (mean, 5th-95th)
Symptom 72.5(19.5) 63.5(21.0) <0.05 70.0(17.5) 62.0(18.7) <0.05
Activity 66.3(16.8) 48.0(18.4) <0.05 61.3(17.5) 47.8(19.5) <0.05
Effect 56.6(18.2) 32.0(15.4) <0.05 48.0(18.6) 30.7(18.8) <0.05
Total 61.5(17.3) 40.6(16.4) <0.05 55.3(16.2) 40.4(17.8) <0.05
COPD severity (Percentage%)
I 14(7.0) 149(16.6) <0.05 25(6.4) 138(19.5) <0.05
II 70(34.8) 390(43.4) <0.05 118(30.0) 342(48.4) <0.05
III 65(32.3) 224(24.9) <0.05 123(31.3) 166(23.5) <0.05
IV 52(25.9) 136(15.1) <0.05 127(32.3) 61(8.6) <0.05
Comorbid anxiety NA NA NA 165(42.0) 36(5.1) <0.05
Comorbid depression 145(72.1) 248(27.6) <0.05 NA NA NA
Female sex 41(20.4) 232(25.8) <0.05 112(28.5) 161(22.7) <0.05
HADS: Hospital Anxiety and Depression Scale: HADS-A: HADS—anxiety; HADS-D: HADS—depression; FEV1, forced expiratory volume in one second; FVC, forced
vital capacity; BMI:body mass index; 6MWD: six-minute walking distance; MRC: Medical Research Council; SGRQ: Saint George’s Respiratory Questionnaire: BODE:
body mass index, degree of airway obstruction, dyspnea and exercise capacity; Possible anxiety (8 ≤ HADS-A ≤ l0) and probable anxiety (HADS-A ≥ 11) were
combined and referred to as anxiety (HADS-A ≥ 8). Possible depression (8 ≤ HADS-D ≤ l0) and probable depression (HADS-D ≥ 11) were combined and referred to
and as depression (HADS-D ≥ 8).
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pressive symptoms had significantly higher mean scores
on the HADS (p <0.0001) (Table 3), and their symptoms
of depression were positively correlated with anxious
symptom (r = 0.701, p < 0.0001). The scores for anxious
and depressive symptoms were correlated much more
closely with the BODE index (r = 0.356, p <0.001; r =
0.386, p < 0.001; respectively) than with FEV1% (r =
−0.072, p >0.05; r = −0.102, p >0.05; respectively).
Determinants of anxiety and depression in patients with
COPD
COPD was associated with a greater risk of anxious
symptoms in both unadjusted (OR 4.02; 95% CI: 3.04 to
5.31) and adjusted multivariable analyses (OR 3.26; 95%
CI: 1.69–5.36; see Table 4). Anxious symptoms were
associated with several demographic and other personal
factors including younger age, female sex, higher educa-
tion level, lower household income, history of smoking,
BODE index, SGRQ and comorbid depressive symptoms
using a multivariate logistic analysis. However, no signifi-
cant difference was observed between patients with or
without anxiety with respect to FEV1, FVC, or FEV1/
FVC (Table 4). This pattern of results was similar forcontrol subjects without COPD. A multivariate logistic
analysis identified six variables related to increased risk
for clinically relevant depressive symptoms (p <0.05).
These were younger age, female sex, higher education
level, and lower household income, history of smoking,
BODE index, SGRQ and comorbid anxious symptoms.
However, no significant difference was observed between
patients with or without depression regarding FEV1,
FVC, or FEV1/ FVC (Table 4). COPD was related to a
higher risk of depressive symptoms in both unadjusted
(OR 7.18; 95% CI: 5.67–9.10) and adjusted multivariable
analyses (OR 3.58; 95% CI: 2.86–5.70; see Table 4).
Anxiety and depression and COPD-related outcomes
Anxiety and depressive symptoms were associated with
poorer patient-centered outcomes. Table 3 shows that
anxious patients had a higher proportion of concurrent
depressive symptoms, a shorter 6MWD, more severe
dyspnea, worse SGRQ, a higher COPD severity and a
higher BODE index as compared with non-anxious
patients.Similar results were found for depressed
patients compared with non- depressed patients with re-
spect to concurrent depression, 6MWD, dyspnea, SGRQ
and the BODE index. Higher COPD severity, as
Table 4 Risk of anxious and depressive symptoms in patients with COPD: multivariate logistic modeling
Factors Anxiety Depression
Odds ratio 95% confidence interval (CI) p Odds ratio 95% confidence interval (CI) p
Age 1.16 1.12–1.19 0.000 1.13 1.05–1.20 0.003
Female gender 1.12 1.03–2.23 0.000 1.12 1.10–1.19 0.000
Education level 1.15 1.10–1.18 0.000 1.09 1.01–1.17 0.012
Household income 1.30 1.14–1.50 0.001 1.26 1.06–1.52 0.000
History of smoking 1.27 1.03–2.35 0.000 1.26 1.15–1.45 0.000
;FEV1 1.09 0.96–1.24 0.099 0.98 0.82–1.17 0.103
FVC 0.99 0.821–1.14 0.113 0.83 0.63–1.07 0.122
FEV1/FVC 0.97 0.88–1.08 0.102 1.02 0.94–1.09 0.098
BODE index 1.47 1.15–1.92 0.001 1.51 1.13–1.95 0.000
;SGRQ 1.35 1.11–1.87 0.000 1.47 1.12–2.01 0.000
Depression 3.26 1.69–5.36 0.000
Anxiety 3.58 2.86–5.70 0.000
FEV1, forced expiratory volume in one second; FVC, forced vital capacity; BODE: body mass index, degree of airway obstruction, dyspnea and exercise capacity;
SGRQ: Saint George’s Respiratory Questionnaire.
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greater risk of anxiety and depressive symptoms among
patients with COPD (Table 2). The BODE index and
concurrent anxious symptoms were related to depressive
symptoms, whereas the BODE index and concurrent de-
pressive symptoms were associated with anxious symp-
toms. For each unit increase in the BODE index, the
anxiety risk increased by 56.2% (OR 1.72; 95% CI: 1.28–
2.31), and the depression risk increased by 48.7% (OR
1.56; 95% CI: 1.23–2.01). Co-morbid anxious symptoms
increased the risk for depressive symptoms by 36.9%
(OR 3.25; 95% CI: 1.67–5.35), and co-morbid depressive
symptoms increased the risk for anxious symptoms by
44.5% (OR 3.56; 95% CI: 2.85–5.68).
The multivariate logistic regression model was used
to explore which components of the BODE index were
independently associated with anxious and depressive
symptoms. The FEVl%, BMI, MRC and 6MWD were
used as the independent variables. The results showed
that MRC and 6MWD were independent predictors
for anxious symptoms and FEVl% and MRC were
independent predictors for depressive symptoms
(Table 5).Table 5 Multivariate logistic regression of the components of
Variables Anxiety
Odds ratio 95% confidence interval (CI) P
BMI (kg/m2) 0.953 0.871~1.043 0
FEVl% 0.989 0.946~1.028 0
6MWD (m) 1.51 1.39~1.64 0
MRC 2.04 1.76~2.36 0
BMI, body mass index;FEV1, forced expiratory volume in one second;6MWD: six-minDiscussion
The present study found a higher prevalence of depres-
sive and anxious symptoms among patients with COPD
in China compared to a matched healthy control group
without the condition, while the scores for anxious and
depressive symptoms were higher among the patients
with COPD than among the controls. Previous studies
have reported anxiety symptoms ranging from 9.57–
49%, and depressive symptoms ranging from 22.8–52%,
using the HADS as the screening tool [12,26,27]. Our
findings confirmed a higher frequency of anxious
(18.3%) and depressive symptoms (35.7%) in stable
COPD patients. Higher percentages of patients with
COPD than of controls reported symptoms of depres-
sion, while anxiety was also more common in the
patients than in the controls. These high rates stress the
importance of screening and treatment of depression
and anxiety in patients with COPD to maintain health-
related quality of life [28].
Of importance was our result that more COPD
patients with anxiety had depression than COPD
patients with depression had anxiety. Given that there
was a significant correlation between anxiety andthe bode index on anxious and depressive symptoms
Depression
Odds ratio 95% confidence interval (CI) P
.105 0.973 0.896~1.057 0.123
.099 1.25 1.16~1.34 0.000
.000 0.995 0.991~1.08 0.159
.000 2.01 1.77~2.29 0.000
ute walking distance; MRC: Medical Research Council.
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tioners that when patients have symptoms of anxiety or
depression, the other condition should be suspected as
well. The prevalence of anxious and depressive symp-
toms increased with the GOLD stage and BODE index,
as established in previous studies [29-31]. These corre-
sponding increases suggest that when the general practi-
tioner detects poorer health status in patients with
COPD, they should consider giving psychological guid-
ance along with medical treatment.
The present study showed a correlation between de-
pressive or anxious symptoms and age, sex, education
level, household income, history of smoking, BODE
index, SGRQ and co-morbid anxious or depressive
symptoms, which was partially consistent with the
results of previous studies [27,31-33]. This is of rele-
vance for practice: general practitioners need to be
aware that anxiety and depression are common condi-
tions in COPD patients. The present result found that
patients who were younger, females, a higher education
level, lower household income, higher BODE index,
higher SGRQ scores and a history of smoking suffered
from anxious or depressive symptoms more frequently.
The relationship of age to anxiety and depression in
patients with COPD has been investigated by Cleland
et al. [28]. A previous study has reported susceptibility
to depression in female patients with COPD [32]. Con-
sistent with this result, our data confirmed that the fre-
quency of depression in female patients with COPD
differed significantly from that in male patients with
COPD, unlike the report from Cleland et al. [28]. This is
likely due to different study populations. The majority of
women in rural areas in China are housewives, and
when they become ill, it means that the family has no
food to eat, which may produce more anxiety and de-
pression. The increase in anxiety and depression with
advancing educational level could be due to the lower
education level of our participants; they were all junior
high school level. Their understanding of COPD is less,
so they may be more prone to anxiety and depression.
The COPD patients who had low family income tended
to suffer from anxiety and depression, perhaps because
there were no local medical treatment safeguard mea-
sures. Patients with a higher degree of airflow limitation
reported more symptoms of depression and increased
risk for depression, and pulmonary functioning was
found to be a predictor of depression [34,35]. However,
FEVl alone was not capable of predicting the presence of
anxiety or depression [12]. In the present study, the FEVl
had no clear relation with anxiety or depression scores.
The BODE index had a stronger association with anx-
ious and depressive symptoms than did the FEVl in our
study, consistent with the results of previous studies
[21,26,27,35]. Our results also confirmed that the SGRQwas related to anxiety and depression in the patients
with COPD. This revealed that the decline in the quality
of life can lead to the generation of anxiety and depres-
sion, and vice versa, anxiety and depression can lead to
reduced quality of life.
We found a strong positive correlation between BODE
index and GOLD stage. Although considerable overlap
between stages was also found within BODE quartiles,
the BODE index can indeed be used to discern groups
of COPD patients. This suggest that the BODE index
could better reflect the anxiety and depression status of
patients with COPD [36].
Our data indicated that subjects who were anxious
and depressive walked a shorter six-minute walking dis-
tance (6MWD), had more dyspnea, a higher BODE
index, and lower SGRQ. The anxiety and depression
scores and the prevalence of anxious and depressive
symptoms increased as BODE quartiles increased. From
the binary logistic regression results, the BODE index
was an independent predictor for anxious and depressive
symptoms after being adjusted for other confounders.
To explore the association between anxious and depres-
sive symptoms and the components of the BODE index,
a binary logistic regression model was used to analyze
the relation. The results showed that anxiety was asso-
ciated with shorter distances walked (6MWD)and dys-
pnea (MRC); however, depression was associated with
FEV1% and more dyspnea (MRC).
Although this is, to date, the largest study to evaluate
the frequency and risk factors associated with depression
and anxiety in Chinese patients with COPD, it has cer-
tain limitations. Although we used a reliable and valid
measure of anxiety and depression, our measure was not
a clinical diagnosis of a generalized anxiety and depres-
sion disorder. We were also not able to evaluate changes
in anxiety and depression over time. In addition, there is
the possibility of misclassification of COPD, although we
took rigorous steps to avoid this.
Conclusion
Patients with COPD are at increased risk for depressive
and anxious symptoms. The patients who had younger
age, female sex, higher education level, lower household
income, higher BODE index, higher SGRQ scores and a
history of smoking were more likely to suffer from anx-
ious or depressive symptoms. Subjects who were anxious
and depressive walked a shorter six-minute walking dis-
tance (6MWD), had more dyspnea, a higher BODE
index, and lower SGRQ. The present study adds evi-
dence for the usefulness of the BODE index to assess
how anxious and depressive symptoms impact the health
outcomes of patients with COPD. The BODE index was
shown to be closely related to anxious and depressive
symptoms in stable COPD patients. Contrary to
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COPD severity assessed by the BODE index can be more
directly related to self-perceived symptoms (dyspnea),
difficulties with activities of daily life, and physical
mobility (exercise capacity), which were the risk fac-
tors for anxious and depressive symptoms. The BODE
index should be included when assessing COPD se-
verity given that anxiety and depression are signifi-
cant co-morbidities of COPD and can be treated.
Our findings show the importance of screening for de-
pressive and anxious symptoms in patients with COPD,
particularly those with younger age, higher SGRQ,
higher BODE index, or history of smoking, so as to pro-
vide adequate patient care. Further studies are needed to
elucidate the effectiveness of treating psychiatric distress
in these patients, as well as the efficacy of screening to
identify those who might benefit from specific therapy.
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